Our Products

Indaflex ™
AlphaRx is presently focusing on Indaflex ™ which has shown excellent activities in the animal model, has multi-billion dollar markets and limited competition. Indaflex ™ is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation intended to be used in the treatment of arthritis. Arthritis is the most common chronic condition in North America and afflicts an estimated 10% of the world's population. Indaflex ™'s active ingredient, Indomethacin, has a long-standing and proven clinical treatment record. With AlphaRx's enhanced proprietary delivery system, its clinical effectiveness is thought to be significantly enhanced. Topical Indaflex ™ delivery is intended to circumvent the significant GI side-effects found with orally ingested NSAID's.

Rifamsolin™
Rifamsolin™  is encapsulating Rifampicin, an antibiotic mainly used to treat tuberculosis, in nanoparticles for intracellular delivery. This early stage drug candidate is currently going through in-vitro and in-vivo studies including biodistribution studies, evaluation of the efficacy in murine infection models and toxicological studies.
Mycobacterium tuberculosis ("TB") is the leading cause of death among HIV positive and infected patients in U.S. Traditional treatment regimen is long and patient compliance is low. The Company believes that by successfully delivering Rifampicin inside the human cell, its efficacy may be substantially increased.

Zysolin™
Zysolin™ is a nanoparticle encapsulated formulation of Gentamicin, a broad spectrum antibiotic, also targeted for intracellular delivery. This drug candidate is currently undergoing in-vivo studies including:  biodistribution studies, evaluation of the efficacy in murine infection models and toxicological studies. HAP is the second most common hospital-acquired infection. It affects approximately 300,000 patients in the United States annually and is associated with mortality rates of  30 to 33 percent for hospitalized patients and mortality rates as high as 70% for patients in the ICU setting. The Company hopes to advance Zisolin™ into the clinical approval phase by mid-2007.

Binoxan™
Binoxan™ is a topical, non-acidic, non-steroidal anti-inflammatory pro-drug in a colloidal formulation, intended for the treatment of ocular inflammation, eye pain and photophobia. Based upon prescription data compiled by IMS Health, it is estimated that over 8.6 million prescriptions are written annually in U.S. for topical ophthalmic anti-inflammatory agents, with sales in excess of $400 M USD.

Ocusolin™
Ocusolin™ is a topical ophthalmic solution utilizing Gentamicin, in a nanoparticulate formulation,  that is effective against a broad spectrum of bacteria including strains resistant to more than one antibiotic. The Company believes Ocusolin™ has the potential to become one of the leading topical antibiotics in the U.S. due to its broad antimicrobial spectrum, its’ ability to eradicate resistant bacteria, its’ ability to penetrate the surface of the eye and potential “twice-a-day” dosing in contrast to the ‘four-times-a-day” dosing of existing products with similar clinical indications. The Company is advancing Ocusolin™ into animal studies in China and hopes to begin clinical studies by mid-2007.

LT0155
AL0155 is a topical ophthalmic solution combining an antibiotic and NSAID in a colloidal formulation intended for the treatment of ocular inflammation and ocular infection. This early stage drug candidate is currently going through in-vivo studies including biodistribution study, evaluation of the efficacy in murine infection models and toxicological studies.

Vansolin™
Vansolin™ is encapsulating Vancomycin, a broad spectrum antibiotic, in the Company's nanoparticulate drug delivery platform for intracellular delivery. This early stage drug candidate is currently going through in-vitro and in-vivo studies including biodistribution study, evaluation of the efficacy in murine infection models and toxicological studies.